A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

Recruiting now · Phase 1

Conditions studied: Breast Cancer

In brief

The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).

Key facts

Study ID
NCT05628870
Run by
Shandong Suncadia Medicine Co., Ltd.
People needed
102
Starts
2023-02-07
Expected to finish
2025-06-30
Last updated by the study team
2025-03-17

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.